(VIANEWS) – Equus Total Return (EQS), LGI Homes (LGIH), Laureate Education (LAUR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Equus Total Return (EQS)
139.2% sales growth and 7.5% return on equity
Equus Total Return, Inc. is a business development company (BDC) specializing in leveraged buyouts, management buyouts, corporate partnerships/joint ventures, growth and expansion capital, acquisition financing, roll-up acquisition strategies, operational turnarounds, recapitalizations of existing businesses, special situations, equity and equity-oriented securities issued by privately owned companies, debt securities including subordinate debt, debt convertible into common or preferred stock, or debt combined with warrants and common and preferred stock, and preferred equity financing. It invests in small to mid-sized companies and acts as a lead investor. It invests in technology, telecommunication, financial services, natural resource and industrial manufacturing and services. It invests in companies engaged in the alternative energy, real estate, healthcare, education, e-learning, leisure and entertainment, and foreign investment sector in the United States, China, India, and Europe. It investments include common and preferred stock, debt convertible into common or preferred stock, debt combined with warrants and options, and other rights to acquire common or preferred stock. It seeks to invest in companies between $1 million to $25 million with revenues between $5 million and $150 million with EBITDA between $2 million to $50 million. It seeks to take control and non-control equity positions. Equus Total Return, Inc. was founded in 1991 and is based in Houston, Texas with additional office in Vancouver, Canada.
Earnings Per Share
As for profitability, Equus Total Return has a trailing twelve months EPS of $0.22.
PE Ratio
Equus Total Return has a trailing twelve months price to earnings ratio of 6.73. Meaning, the purchaser of the share is investing $6.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.5%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Aug 20, 2009, the estimated forward annual dividend yield is 4.61%.
2. LGI Homes (LGIH)
40.2% sales growth and 12.61% return on equity
LGI Homes, Inc. designs, constructs, and sells homes in the United States. It offers entry-level homes, such as detached and attached homes, and move-up homes under the LGI Homes brand name; and luxury series homes under the Terrata Homes brand name. As of December 31, 2020, it owned 113 communities. The company serves in Texas, Arizona, Florida, Georgia, New Mexico, Colorado, North Carolina, South Carolina, Washington, Tennessee, Minnesota, Oklahoma, Alabama, California, Oregon, Nevada, West Virginia, Virginia, and Pennsylvania. LGI Homes, Inc. was founded in 2003 and is headquartered in The Woodlands, Texas.
Earnings Per Share
As for profitability, LGI Homes has a trailing twelve months EPS of $8.35.
PE Ratio
LGI Homes has a trailing twelve months price to earnings ratio of 11.21. Meaning, the purchaser of the share is investing $11.21 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.61%.
3. Laureate Education (LAUR)
19.7% sales growth and 10.09% return on equity
Laureate Education, Inc., together with its subsidiaries, provides higher education programs and services to students through a network of universities and higher education institutions. It offers a range of undergraduate and graduate degree programs primarily in the areas of business and management, medicine and health sciences, and engineering and information technology through campus-based, online, and hybrid programs. The company provides its services in Brazil, Mexico, Chile, Peru, and the United States. The company was formerly known as Sylvan Learning Systems, Inc. and changed its name to Laureate Education, Inc. in May 2004. The company was founded in 1989 and is headquartered in Baltimore, Maryland.
Earnings Per Share
As for profitability, Laureate Education has a trailing twelve months EPS of $0.6.
PE Ratio
Laureate Education has a trailing twelve months price to earnings ratio of 23.9. Meaning, the purchaser of the share is investing $23.9 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.09%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Laureate Education’s EBITDA is 17.44.
Yearly Top and Bottom Value
Laureate Education’s stock is valued at $14.34 at 11:22 EST, under its 52-week high of $14.81 and way higher than its 52-week low of $9.24.
Moving Average
Laureate Education’s worth is higher than its 50-day moving average of $14.09 and way above its 200-day moving average of $12.33.
Revenue Growth
Year-on-year quarterly revenue growth grew by 19.9%, now sitting on 1.36B for the twelve trailing months.
4. Exelixis (EXEL)
16.2% sales growth and 6.68% return on equity
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Earnings Per Share
As for profitability, Exelixis has a trailing twelve months EPS of $0.5.
PE Ratio
Exelixis has a trailing twelve months price to earnings ratio of 42.72. Meaning, the purchaser of the share is investing $42.72 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.68%.
Sales Growth
Exelixis’s sales growth is 14.7% for the ongoing quarter and 16.2% for the next.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 21.7% and positive 300% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12%, now sitting on 1.71B for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Exelixis’s EBITDA is 59.53.
5. Esquire Financial Holdings (ESQ)
15.4% sales growth and 23.5% return on equity
Esquire Financial Holdings, Inc. operates as the bank holding company for Esquire Bank, National Association that provides commercial banking products and services to legal industry and small businesses, and commercial and retail customers in the United States. The company offers checking, savings, money market, and time deposits, as well as certificates of deposit. It also provides commercial loans, including short-term financing for inventory, receivables, the purchase of supplies, or other operating needs arising during the normal course of business, as well as loans to its qualified merchant customers; commercial lines of credit; consumer loans consisting of post-settlement consumer and structured settlement loans to plaintiffs and claimants, as well as loans to individuals for debt consolidation, medical expenses, living expenses, payment of outstanding bills, or other consumer needs; and real estate loans, such as multifamily, 1-4 family residential, commercial real estate, and construction loans, as well as merchant services. As of December 31, 2020, the company operated a full-service branch in Jericho, New York; and an administrative office in Boca Raton, Florida. Esquire Financial Holdings, Inc. was founded in 2006 and is headquartered in Jericho, New York.
Earnings Per Share
As for profitability, Esquire Financial Holdings has a trailing twelve months EPS of $4.61.
PE Ratio
Esquire Financial Holdings has a trailing twelve months price to earnings ratio of 9.47. Meaning, the purchaser of the share is investing $9.47 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.5%.
Volume
Today’s last reported volume for Esquire Financial Holdings is 24149 which is 14.23% above its average volume of 21140.
Yearly Top and Bottom Value
Esquire Financial Holdings’s stock is valued at $43.66 at 11:22 EST, way under its 52-week high of $54.03 and way higher than its 52-week low of $34.75.
Moving Average
Esquire Financial Holdings’s worth is under its 50-day moving average of $46.50 and under its 200-day moving average of $43.75.
6. Sotherly Hotels (SOHO)
14.4% sales growth and 28.02% return on equity
Sotherly Hotels Inc. is a self-managed and self-administered lodging REIT focused on the acquisition, renovation, upbranding and repositioning of upscale to upper-upscale full-service hotels in the Southern United States. Currently, the Company's portfolio consists of investments in twelve hotel properties, comprising 3,156 rooms, as well as interests in two condominium hotels and their associated rental programs. The Company owns hotels that operate under the Hilton Worldwide, Hyatt Hotels Corporation, and Marriott International, Inc. brands, as well as independent hotels. Sotherly Hotels Inc. was organized in 2004 and is headquartered in Williamsburg, Virginia.
Earnings Per Share
As for profitability, Sotherly Hotels has a trailing twelve months EPS of $0.28.
PE Ratio
Sotherly Hotels has a trailing twelve months price to earnings ratio of 5.5. Meaning, the purchaser of the share is investing $5.5 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.02%.
7. Universal Health Services (UHS)
6.1% sales growth and 11.27% return on equity
Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities. The company operates through Acute Care Hospital Services and Behavioral Health Care Services segments. Its hospitals offer general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic and coronary care, pediatric services, pharmacy services, and/or behavioral health services. The company also provides commercial health insurance services; and various management services, which include central purchasing, information, finance and control systems, facilities planning, physician recruitment, administrative personnel management, marketing, and public relations services. Universal Health Services, Inc. founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
Earnings Per Share
As for profitability, Universal Health Services has a trailing twelve months EPS of $9.62.
PE Ratio
Universal Health Services has a trailing twelve months price to earnings ratio of 12.98. Meaning, the purchaser of the share is investing $12.98 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.27%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 6.3% and a negative 2.6%, respectively.
Moving Average
Universal Health Services’s worth is below its 50-day moving average of $129.42 and under its 200-day moving average of $137.53.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Aug 30, 2023, the estimated forward annual dividend rate is 0.8 and the estimated forward annual dividend yield is 0.63%.
Yearly Top and Bottom Value
Universal Health Services’s stock is valued at $124.89 at 11:22 EST, way under its 52-week high of $158.57 and way higher than its 52-week low of $82.50.
